rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2023-292-297rsp-3356Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESСистемная красная волчанка и беременность: до, во время гестации и после родовSystemic lupus erythematosus and pregnancy: Before gestation, during and after childbirthhttps://orcid.org/0000-0003-3552-2522РешетнякТ. М.ReshetnyakT. M.

115522, Москва, Каширское шоссе, 34а

115522, Moscow, Kashirskoye Highway, 34A

t_reshetnyak@yahoo.comhttps://orcid.org/0000-0002-6018-3895КошелеваН. М.KoshelevaN. M.

115522, Москва, Каширское шоссе, 34а

115522, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0002-1598-8360НасоновЕ. Л.NasonovE. L.

115522, Москва, Каширское шоссе, 34а

115522, Moscow, Kashirskoye Highway, 34A

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation202328062023613292297Copyright © Решетняк Т.М., Кошелева Н.М., Насонов Е.Л., 20232023Решетняк Т.М., Кошелева Н.М., Насонов Е.Л.Reshetnyak T.M., Kosheleva N.M., Nasonov E.L.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3356

Системная красная волчанка (СКВ) – это заболевание женщин репродуктивного возраста. До определенного времени считалось, что пациенткам с СКВ беременность противопоказана. Совершенствование методов лечения заболевания, а также результаты, полученные при изучении безопасности лекарств, позволяют говорить о возможности беременности для большинства пациенток с СКВ. Решающее значение имеет тщательное планирование беременности, когда болезнь хорошо контролируется с помощью лекарств, совместимых с беременностью. Этому способствует и ведение пациенток совместно врачами разных специальностей (ревматологом, нефрологом, эндокринологом, акушером и др.). В статье обсуждается тактика ведения женщин с СКВ на этапе планирования беременности, во время беременности и после родоразрешения. 

Systemic lupus erythematosus (SLE) is a disease of women of reproductive age. Up to a certain time, pregnancy was contraindicated in patients with SLE, improving the management of the disease itself (monitoring), as well as understanding the safety of drugs make pregnancy possible for most patients with SLE. Careful pregnancy planning is crucial when the disease is well controlled with pregnancy-compatible medications. This is also facilitated by the management of patients jointly by doctors of different specialties (rheumatologist, neurologist, endocrinologist, etc.) with obstetricians. The article discusses the achievements of managing women with SLE during pregnancy planning, during pregnancy and after delivery.

системная красная волчанкабеременностьпослеродовый периодлекарственные препаратыsystemic lupus erythematosuspregnancypostpartum periodmedicationsСтатья подготовлена в рамках фундаментальной темы FURS-2022-003 (№ 1220404000-7.)ReferencesНасонова ВА. Системная красная волчанка. М.:Медицина; 1972.Nasonova VA. Systemic lupus erythematosus. Moscow: Meditsina;1972 (In Russ.).Насонов ЕЛ, Соловьев СК, Аршинов АВ. Системная красная волчанка: история и современность. Научно-практическая ревматология. 2022;60(4):397-412. doi: 10.47360/1995-4484-2022-397-412Nasonov EL, Soloviev SK, Arshinov AV. Systemic lupus erythematosus: History and modernity. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022;60(4):397-412 (In Russ.). doi: 10.47360/1995-4484-2022-397-412Соловьев СК, Асеева ЕА, Попкова ТВ, Лила АМ, Мазуров ВИ, Насонов ЕЛ. Системная красная волчанка: новые горизонты диагностики и терапии. Научно-практическая ревматология. 2020;58(1):5-14. doi: 10.14412/1995-4484-2020-5-14Solovyev SK, Aseeva EA, Popkova TV, Lila AM, Mazurov VI, Nasonov EL. Systemic lupus erythematosus: New horizons for diagnosis and therapy. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2020;58(1):5-14 (In Russ.). doi: 10.14412/1995-4484-2020-5-14Andreoli L, Bertsias GK, Agmon-Levin N, Brown S, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017;76(3):476-485. doi: 10.1136/annrheumdis-2016-209770Andreoli L, Bertsias GK, Agmon-Levin N, Brown S, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017;76(3):476-485. doi: 10.1136/annrheumdis-2016-209770Насонов ЕЛ, Попкова ТВ, Лила АМ. Белимумаб в лечении системной красной волчанки: 20 лет фундаментальных исследований, 10 лет клинической практики. Научно-практическая ревматология. 2021;59(4):367-383. doi: 10.47360/1995-4484-2021-367-383Nasonov EL, Popkova TV, Lila AM. Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(4):367-383 (In Russ.). doi: 10.47360/1995-4484-2021-367-383Sammaritano LR, Bermas BL, Chakravarty EE, Chambers C, Clowse MEB, Lockshin MD, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol. 2020;72(4):529-556. doi: 10.1002/art.41191Sammaritano LR, Bermas BL, Chakravarty EE, Chambers C, Clowse MEB, Lockshin MD, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol. 2020;72(4):529-556. doi: 10.1002/art.41191Götestam Skorpen C, Hoeltzenbein M, Tincani A, FischerBetz R, Elefant E, Chambers C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75(5):795-810. doi: 10.1136/annrheumdis-2015-208840Götestam Skorpen C, Hoeltzenbein M, Tincani A, FischerBetz R, Elefant E, Chambers C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75(5):795-810. doi: 10.1136/annrheumdis-2015-208840Alijotas-Reig J, Esteve-Valverde E, Ferrer-Oliveras R, Sáez-Comet L, Lefkou E, Mekinian A, et al.; EUROAPS Study Group. The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases. Autoimmun Rev. 2019;18(4):406-414. doi: 10.1016/j.autrev.2018.12.006Alijotas-Reig J, Esteve-Valverde E, Ferrer-Oliveras R, Sáez-Comet L, Lefkou E, Mekinian A, et al.; EUROAPS Study Group. The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases. Autoimmun Rev. 2019;18(4):406-414. doi: 10.1016/j.autrev.2018.12.006Gasparotto M, Gatto M, Binda V, Doria A, Moroni G. Lupus nephritis: Clinical presentations and outcomes in the 21st century. Rheumatology (Oxford). 2020;59(Suppl 5):39-51. doi: 10.1093/rheumatology/keaa381.Gasparotto M, Gatto M, Binda V, Doria A, Moroni G. Lupus nephritis: Clinical presentations and outcomes in the 21st century. Rheumatology (Oxford). 2020;59(Suppl 5):39-51. doi: 10.1093/rheumatology/keaa381.Lucas A, Eudy AM, Gladman D, Petri M, Urowitz M, Wyatt CM, et al. The association of lupus nephritis with adverse pregnancy outcomes among women with lupus in North America. Lupus. 2022;31(11):1401-1407. doi: 10.1177/09612033221123251Lucas A, Eudy AM, Gladman D, Petri M, Urowitz M, Wyatt CM, et al. The association of lupus nephritis with adverse pregnancy outcomes among women with lupus in North America. Lupus. 2022;31(11):1401-1407. doi: 10.1177/09612033221123251Petri M, Landy H, Clowse MEB, Gemzoe K, Khamashta M, Kurtinecz M, et al. Belimumab use during pregnancy: A summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports. Ann Rheum Dis. 2023;82(2):217-225. doi: 10.1136/ard-2022-222505Petri M, Landy H, Clowse MEB, Gemzoe K, Khamashta M, Kurtinecz M, et al. Belimumab use during pregnancy: A summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports. Ann Rheum Dis. 2023;82(2):217-225. doi: 10.1136/ard-2022-222505Bragnes Y, Boshuizen R, de Vries A, Lexberg Å, Østensen M. Low level of Rituximab in human breast milk in a patient treated during lactation. Rheumatology (Oxford). 2017;56(6):1047-1048. doi: 10.1093/rheumatology/kex039Bragnes Y, Boshuizen R, de Vries A, Lexberg Å, Østensen M. Low level of Rituximab in human breast milk in a patient treated during lactation. Rheumatology (Oxford). 2017;56(6):1047-1048. doi: 10.1093/rheumatology/kex039Juliao P, Wurst K, Pimenta JM, Gemzoe K, Landy H, Moody MA, et al. Belimumab use during pregnancy: Interim results of the belimumab pregnancy registry. Birth Defects Res. 2023;115(2):188-204. doi: 10.1002/bdr2.2091Juliao P, Wurst K, Pimenta JM, Gemzoe K, Landy H, Moody MA, et al. Belimumab use during pregnancy: Interim results of the belimumab pregnancy registry. Birth Defects Res. 2023;115(2):188-204. doi: 10.1002/bdr2.2091Danve A, Perry L, Deodhar A. Use of belimumab throughout pregnancy to treat active systemic lupus erythematosus: A case report. Semin Arthritis Rheum. 2014;44(2):195-197. doi: 10.1016/j.semarthrit.2014.05.006Danve A, Perry L, Deodhar A. Use of belimumab throughout pregnancy to treat active systemic lupus erythematosus: A case report. Semin Arthritis Rheum. 2014;44(2):195-197. doi: 10.1016/j.semarthrit.2014.05.006Lai Y, Li B, Huang J, Du J, Yue M, Shen X, et al. Different pregnancy outcomes in patients with systemic lupus erythematosus treated with belimumab. Lupus. 2023;32(1):149-154. doi: 10.1177/09612033221141805Lai Y, Li B, Huang J, Du J, Yue M, Shen X, et al. Different pregnancy outcomes in patients with systemic lupus erythematosus treated with belimumab. Lupus. 2023;32(1):149-154. doi: 10.1177/09612033221141805Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306. doi: 10.1111/j.1538-7836.2006.01753.xMiyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306. doi: 10.1111/j.1538-7836.2006.01753.xНасонов ЕЛ (ред.). Антифосфолипидный синдром. М.:Литтерра;2004.Nasonov EL (ed.). Antiphospholipid syndrome. Moscow:Litterra;2004 (In Russ.).Решетняк ТМ. Антифосфолипидный синдром: диагностика и клинические проявления (лекция). Научно-практическая ревматология. 2014;52(1):56-71. doi: 10.14412/1995-4484-2014-56-71Reshetnyak TM. Antiphospholipid syndrome: diagnosis and clinical manifestations (a lecture). Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2014;52(1):56-71 (In Russ.). doi: 10.14412/1995-4484-2014-56-71Meroni PL, Borghi MO. Antiphospholipid antibody assays in 2021: Looking for a predictive value in addition to a diagnostic one. Front Immunol. 2021;12:726820. doi: 10.3389/fimmu.2021.726820Meroni PL, Borghi MO. Antiphospholipid antibody assays in 2021: Looking for a predictive value in addition to a diagnostic one. Front Immunol. 2021;12:726820. doi: 10.3389/fimmu.2021.726820Решетняк ТМ, Чельдиева ФА, Нурбаева КС, Лила АМ, Насонов ЕЛ. Антифосфолипидный синдром: диагностика, механизм развития, вопросы терапии. Тромбоз, гемостаз и реология. 2020;(4):4-21. doi: 10.25555/THR.2020.4.0940Reshetnyak TM, Cheldieva FA, Nurbaeva KS, Lila AM, Nasonov EL. Antiphospholipid syndrome: Diagnosis, development, therapy. Thrombosis, Hemostasis and Rheology. 2020;(4):4-21 (In Russ.). doi: 10.25555/THR.2020.4.0940Alijotas-Reig J, Esteve-Valverde E, Ferrer-Oliveras R, SáezComet L, Lefkou E, Mekinian A, et al.; EUROAPS Study Group. Bleeding and antithrombotic therapy during pregnancy in women with poor aPL-related obstetric outcomes: A survey of 1075 cases from EUROAPS registry. Eur J Anaesthesiol. 2021;38(9):916-922. doi: 10.1097/EJA.0000000000001484Alijotas-Reig J, Esteve-Valverde E, Ferrer-Oliveras R, SáezComet L, Lefkou E, Mekinian A, et al.; EUROAPS Study Group. Bleeding and antithrombotic therapy during pregnancy in women with poor aPL-related obstetric outcomes: A survey of 1075 cases from EUROAPS registry. Eur J Anaesthesiol. 2021;38(9):916-922. doi: 10.1097/EJA.0000000000001484Fredi M, Andreoli L, Bacco B, Bertero T, Bortoluzzi A, Breda S, et al. First report of the Italian Registry on Immune-Mediated Congenital Heart Block (Lu.Ne Registry). Front Cardiovasc Med. 2019;6:11. doi: 10.3389/fcvm.2019.00011Fredi M, Andreoli L, Bacco B, Bertero T, Bortoluzzi A, Breda S, et al. First report of the Italian Registry on Immune-Mediated Congenital Heart Block (Lu.Ne Registry). Front Cardiovasc Med. 2019;6:11. doi: 10.3389/fcvm.2019.00011Costedoat-Chalumeau N, Morel N. Commentary: First report of the Italian Registry on Immune-Mediated Congenital Heart Block (Lu.Ne Registry). Front Cardiovasc Med. 2020;7:83. doi: 10.3389/fcvm.2020.00083Costedoat-Chalumeau N, Morel N. Commentary: First report of the Italian Registry on Immune-Mediated Congenital Heart Block (Lu.Ne Registry). Front Cardiovasc Med. 2020;7:83. doi: 10.3389/fcvm.2020.00083Власова ГА, Перминова СГ, Кошелева НМ. Подходы к реализации репродуктивной функции у женщин с системной красной волчанкой и антифосфолипидным синдромом. Гинекология. 2021;23(2):167-172. doi: 10.26442/20795696.2021.2.20073Vlasova GA, Perminova SG, Kosheleva NM. Approaches to the realization of reproductive function in women with systemic lupus erythematosus and antiphospholipid syndrome. Gynecology. 2021;23(2):167-172 (In Russ.). doi: 10.26442/20795696.2021.2.20073Dao KH, Bermas BL. Systemic lupus erythematosus management in pregnancy. Int J Womens Health. 2022;14:199-211. doi: 10.2147/IJWH.S282604Dao KH, Bermas BL. Systemic lupus erythematosus management in pregnancy. Int J Womens Health. 2022;14:199-211. doi: 10.2147/IJWH.S282604Pasoto SG, Mendonça BB, Bonfá E. Menstrual disturbances in patients with systemic lupus erythematosus without alkylating therapy: Clinical, hormonal and therapeutic associations. Lupus. 2002;11(3):175-180. doi: 10.1191/0961203302lu163oaPasoto SG, Mendonça BB, Bonfá E. Menstrual disturbances in patients with systemic lupus erythematosus without alkylating therapy: Clinical, hormonal and therapeutic associations. Lupus. 2002;11(3):175-180. doi: 10.1191/0961203302lu163oaMa W, Zhan Z, Liang X, Chen J, Huang X, Liao C. Subclinical impairment of ovarian reserve in systemic lupus erythematosus patients with normal menstruation not using alkylating therapy. J Womens Health (Larchmt). 2013;22(12):1023-1027. doi: 10.1089/jwh.2013.4255Ma W, Zhan Z, Liang X, Chen J, Huang X, Liao C. Subclinical impairment of ovarian reserve in systemic lupus erythematosus patients with normal menstruation not using alkylating therapy. J Womens Health (Larchmt). 2013;22(12):1023-1027. doi: 10.1089/jwh.2013.4255Andreoli L, Fredi M, Nalli C, Reggia R, Lojacono A, Motta M, et al. Pregnancy implications for systemic lupus erythematosus and the antiphospholipid syndrome. J Autoimmun. 2012;38(2-3):J197-J208. doi: 10.1016/j.jaut.2011.11.010Andreoli L, Fredi M, Nalli C, Reggia R, Lojacono A, Motta M, et al. Pregnancy implications for systemic lupus erythematosus and the antiphospholipid syndrome. J Autoimmun. 2012;38(2-3):J197-J208. doi: 10.1016/j.jaut.2011.11.010Mehta B, Luo Y, Xu J, Sammaritano L, Salmon J, Lockshin M, et al. Trends in maternal and fetal outcomes among pregnant women with systemic lupus erythematosus in the United States: A cross-sectional analysis. Ann Intern Med. 2019;171(3):164-171. doi: 10.7326/M19-0120Mehta B, Luo Y, Xu J, Sammaritano L, Salmon J, Lockshin M, et al. Trends in maternal and fetal outcomes among pregnant women with systemic lupus erythematosus in the United States: A cross-sectional analysis. Ann Intern Med. 2019;171(3):164-171. doi: 10.7326/M19-0120Alsnes IV, Janszky I, Forman MR, Vatten LJ, Økland I. A population-based study of associations between preeclampsia and later cardiovascular risk factors. Am J Obstet Gynecol. 2014;211(6):1-7. doi: 10.1016/j.ajog.2014.06.026Alsnes IV, Janszky I, Forman MR, Vatten LJ, Økland I. A population-based study of associations between preeclampsia and later cardiovascular risk factors. Am J Obstet Gynecol. 2014;211(6):1-7. doi: 10.1016/j.ajog.2014.06.026Sibai BM. Imitators of severe pre-eclampsia. Semin Perinatol. 2009;33(3):196-205. doi: 10.1053/j.semperi.2009.02.004Sibai BM. Imitators of severe pre-eclampsia. Semin Perinatol. 2009;33(3):196-205. doi: 10.1053/j.semperi.2009.02.004Nalli C, Manfredi L, Fredi M, Crisafulli F, Bertocchi S, Khizroeva J, et al. Managing puerperium in patients with systemic autoimmune diseases: An update. Expert Rev Clin Immunol. 2022;18(4):391-399. doi: 10.1080/1744666X.2022.2050216Nalli C, Manfredi L, Fredi M, Crisafulli F, Bertocchi S, Khizroeva J, et al. Managing puerperium in patients with systemic autoimmune diseases: An update. Expert Rev Clin Immunol. 2022;18(4):391-399. doi: 10.1080/1744666X.2022.2050216Rodríguez Almaraz E, Sáez-Comet L, Casellas M, Delgado P, Ugarte A, Vela-Casasempere P, et al. Pregnancy control in patients with systemic lupus erythematosus/antiphospholipid syndrome. Part 2: Pregnancy follow-up. Reumatol Clin (Engl Ed). 2021;17(3):125-131. doi: 10.1016/j.reuma.2019.09.003Rodríguez Almaraz E, Sáez-Comet L, Casellas M, Delgado P, Ugarte A, Vela-Casasempere P, et al. Pregnancy control in patients with systemic lupus erythematosus/antiphospholipid syndrome. Part 2: Pregnancy follow-up. Reumatol Clin (Engl Ed). 2021;17(3):125-131. doi: 10.1016/j.reuma.2019.09.003Delgado P, Robles Á, Martínez López JA, Sáez-Comet L, Rodríguez Almaraz E, Martínez-Sánchez N, et al. Pregnancy control in patients with systemic lupus erythematosus/antiphospholipid syndrome. Part 3: Childbirth. Puerperium. Breastfeeding Contraception. Newborn. Reumatol Clin (Engl Ed). 2021;17(4):183-186. doi: 10.1016/j.reuma.2019.09.004Delgado P, Robles Á, Martínez López JA, Sáez-Comet L, Rodríguez Almaraz E, Martínez-Sánchez N, et al. Pregnancy control in patients with systemic lupus erythematosus/antiphospholipid syndrome. Part 3: Childbirth. Puerperium. Breastfeeding Contraception. Newborn. Reumatol Clin (Engl Ed). 2021;17(4):183-186. doi: 10.1016/j.reuma.2019.09.004Zhao C, Zhao J, Huang Y, Wang Z, Wang H, Zhang H, et al. New-onset systemic lupus erythematosus during pregnancy. Clin Rheumatol. 2013;32(6):815-822. doi: 10.1007/s10067-013-2180-zZhao C, Zhao J, Huang Y, Wang Z, Wang H, Zhang H, et al. New-onset systemic lupus erythematosus during pregnancy. Clin Rheumatol. 2013;32(6):815-822. doi: 10.1007/s10067-013-2180-zSmyth A, Oliveira GH, Lahr BD, Bailey KR, Norby SM, Garovic VD. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol. 2010;5(11):2060-2068. doi: 10.2215/CJN.00240110Smyth A, Oliveira GH, Lahr BD, Bailey KR, Norby SM, Garovic VD. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol. 2010;5(11):2060-2068. doi: 10.2215/CJN.00240110Pomp ER, Lenselink AM, Rosendaal FR, Doggen CJ. Pregnancy, the postpartum period and prothrombotic defects: Risk of venous thrombosis in the MEGA study. J Thromb Haemost. 2008;6(4): 632-637. doi: 10.1111/j.1538-7836.2008.02921.xPomp ER, Lenselink AM, Rosendaal FR, Doggen CJ. Pregnancy, the postpartum period and prothrombotic defects: Risk of venous thrombosis in the MEGA study. J Thromb Haemost. 2008;6(4): 632-637. doi: 10.1111/j.1538-7836.2008.02921.xAndreoli L, Lazzaroni MG, Carini C, Dall’Ara F, Nalli C, Reggia R, et al. “Disease knowledge index” and perspectives on reproductive issues: A nationwide study on 398 women with autoimmune rheumatic diseases. Joint Bone Spine. 2019;86(4):475-481. doi: 10.1016/j.jbspin.2018.12.002Andreoli L, Lazzaroni MG, Carini C, Dall’Ara F, Nalli C, Reggia R, et al. “Disease knowledge index” and perspectives on reproductive issues: A nationwide study on 398 women with autoimmune rheumatic diseases. Joint Bone Spine. 2019;86(4):475-481. doi: 10.1016/j.jbspin.2018.12.002Wolgemuth T, Stransky OM, Chodoff A, Kazmerski TM, Clowse MEB, Birru Talabi M. Exploring the preferences of women regarding sexual and reproductive health care in the context of rheumatology: A qualitative study. Arthritis Care Res (Hoboken). 2021;73(8):1194-1200. doi: 10.1002/acr.24249Wolgemuth T, Stransky OM, Chodoff A, Kazmerski TM, Clowse MEB, Birru Talabi M. Exploring the preferences of women regarding sexual and reproductive health care in the context of rheumatology: A qualitative study. Arthritis Care Res (Hoboken). 2021;73(8):1194-1200. doi: 10.1002/acr.24249Carandang K, Mruk V, Ardoin SP, Huynh B, Clowse MEB, Berlan ED, et al. Reproductive health needs of adolescent and young adult women with pediatric rheumatic diseases. Pediatr Rheumatol Online J. 2020;18(1):66. doi: 10.1186/s12969-020-00460-7Carandang K, Mruk V, Ardoin SP, Huynh B, Clowse MEB, Berlan ED, et al. Reproductive health needs of adolescent and young adult women with pediatric rheumatic diseases. Pediatr Rheumatol Online J. 2020;18(1):66. doi: 10.1186/s12969-020-00460-7Birru Talabi M, Clowse MEB. Antirheumatic medications in pregnancy and breastfeeding. Curr Opin Rheumatol. 2020;32(3):238-246. doi: 10.1097/BOR.0000000000000710Birru Talabi M, Clowse MEB. Antirheumatic medications in pregnancy and breastfeeding. Curr Opin Rheumatol. 2020;32(3):238-246. doi: 10.1097/BOR.0000000000000710

The authors declare that there are no conflicts of interest present.